Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01280344 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
A Phase 2 study of Gastrointestinal Dysmotility, sponsored by Helsinn Therapeutics (U.S.).
- Completed
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT01280344 is a Phase 2 study of Gastrointestinal Dysmotility that has completed, run by Helsinn Therapeutics (U.S.). The registered enrollment target is 320 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT01280344, a Phase 2 study of Gastrointestinal Dysmotility, has completed, sponsored by Helsinn Therapeutics (U.S.).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
Conditions Studied
Interventions
- DRUG Saline Solution for Injection
- DRUG Ipamorelin
Study Locations (20)
Florida
- - Aventura
- - Inverness
- - Miami
- - Orlando
- - Pensacola
- - Sarasota
- - Tampa
- - Weston
California
- - Fountain Valley
- - Glendale
- - Laguna Hills
- - Los Angeles
- - Orange
- - San Francisco
Alabama
- - Florence
- - Sheffield
Illinois
- - Chicago
- - Highland Park
Colorado
- - Aurora
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01280344
The ClinicalTrials.gov registry entry for NCT01280344 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helsinn Therapeutics (U.S.), which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Dysmotility appearing as the primary indexed condition, and to 2 interventions - of which Saline Solution for Injection is the first listed.
NCT01280344 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT01280344 about?
NCT01280344 is a clinical study titled "Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function". Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
What is the current status of trial NCT01280344?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2011-04. Estimated completion is 2014-05.
What conditions does trial NCT01280344 study?
This clinical trial studies the following conditions: Gastrointestinal Dysmotility.
What interventions are being tested in trial NCT01280344?
The interventions under investigation include: Saline Solution for Injection (DRUG), Ipamorelin (DRUG).
Who is sponsoring clinical trial NCT01280344?
This trial is sponsored by Helsinn Therapeutics (U.S.), which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01280344 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Dysmotility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.